Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
USA 111 , 1421714222 (2014)
Are you eligible for GLP-1 treatments
Vin ung i qua d dy v rut, c gan chuyn ha ri mi vo mu mt cch t t
Current guidelines from the American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity (IFSO) support consideration in patients with BMI 35 kg/m regardless of comorbidities, or BMI 30-34.9 kg/m with metabolic disease
US$ 19.98
US$ 20.40
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
US$ 29.54
